OverviewSuggest Edit

Bio-Path Holdings operates as a clinical and preclinical stage oncology focused antisense drug development company. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. It has a number of drug candidates for the treatment of acute myeloid leukemia, chronic myelogenous leukemia, solid tumors and lymphoma.

TypePublic
Founded2007
HQBellaire, TX, US
Websitebiopathholdings.com

Latest Updates

Employees (est.) (Dec 2019)9(+13%)
Revenue (FY, 2018)$0(-100%)
Share Price (Apr 2021)$5.6
Cybersecurity ratingAMore

Key People/Management at Bio-Path Holdings

Peter Nielsen

Peter Nielsen

President, CEO, CFO, and Chairman of the Board of Directors
Anthony Price

Anthony Price

Senior Vice President of Finance, Accounting & Administration
Michael Hickey

Michael Hickey

Director of Clinical Program Management
Douglas P. Morris

Douglas P. Morris

Director of Investor Relations
Michael Roberts

Michael Roberts

Director of Manufacturing Planning & Engineering
Show more

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, TX, US (HQ)
4710 Bellaire Blvd #210
Show all (1)

Bio-Path Holdings Financials and Metrics

Bio-Path Holdings Revenue

USD

Net income (FY, 2020)

(10.9m)

EBIT (FY, 2020)

(10.9m)

Market capitalization (20-Apr-2021)

38.6m

Closing stock price (20-Apr-2021)

5.6

Cash (31-Dec-2020)

13.8m

EV

25.5m
Bio-Path Holdings's current market capitalization is $38.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

13.0k37.0k

General and administrative expense

1.2m986.1k1.6m2.7m2.5m3.0m3.5m3.4m4.1m4.3m

R&D expense

1.5m1.6m3.0m5.5m5.5m4.6m4.6m6.6m

Operating expense total

1.2m986.1k3.2m4.3m5.5m8.5m9.0m8.0m8.7m10.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

324.6k327.4k231.3k252.2k246.1k239.8k810.2k380.9k754.5k713.4k786.4k566.6k519.9k849.0k757.0k681.0k970.0k845.0k893.0k987.0k852.0k740.0k1.1m966.0k896.0k1.3m1.0m

R&D expense

107.6k517.0k424.5k592.5k564.4k992.4k1.0m1.2m2.3m1.0m1.5m1.6m932.0k827.0k2.3m398.0k1.5m1.4m2.0m1.0m

Operating expense total

324.6k327.4k231.3k252.2k246.1k239.8k810.2k488.5k1.3m1.1m1.4m1.1m1.5m1.9m1.9m3.0m2.0m2.3m2.5m1.9m1.7m3.1m1.5m2.5m2.3m3.3m2.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

952.3k534.0k3.6m13.9m8.9m9.4m6.0m1.0m20.4m13.8m

Accounts Receivable

Prepaid Expenses

48.4k42.6k64.1k100.5k179.0k1.1m332.0k776.0k1.3m

Inventories

USDQ2, 2011

Debt/Equity

0.2 x

Debt/Assets

0.2 x

Financial Leverage

1.1 x
Show all financial metrics

Bio-Path Holdings Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Bio-Path Holdings Online and Social Media Presence

Embed Graph

Bio-Path Holdings News and Updates

Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting

Preclinical Data Support BP1002 Combination Therapy in Venetoclax-resistant AML Patients Preclinical Data Support BP1002 Combination Therapy in Venetoclax-resistant AML Patients

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the sa…

Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others

Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster pr…

Bio-Path Holdings Reports Full Year 2020 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and se…
Show more

Bio-Path Holdings Frequently Asked Questions

  • When was Bio-Path Holdings founded?

    Bio-Path Holdings was founded in 2007.

  • Who are Bio-Path Holdings key executives?

    Bio-Path Holdings's key executives are Peter Nielsen, Anthony Price and Michael Hickey.

  • How many employees does Bio-Path Holdings have?

    Bio-Path Holdings has 9 employees.

  • Who are Bio-Path Holdings competitors?

    Competitors of Bio-Path Holdings include Vivace Therapeutics, MiracleCord and ImmVira.

  • Where is Bio-Path Holdings headquarters?

    Bio-Path Holdings headquarters is located at 4710 Bellaire Blvd #210, Bellaire.

  • Where are Bio-Path Holdings offices?

    Bio-Path Holdings has an office in Bellaire.

  • How many offices does Bio-Path Holdings have?

    Bio-Path Holdings has 1 office.